- Investigator
- James Wymer
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Amyotrophic Lateral Sclerosis , 31 publications
- Deglutition Disorders , 11 publications
- Deglutition , 10 publications
- Cough , 5 publications
Research activity
Active clinical trials
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
- Investigator
- James Wymer
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Investigator
- James Wymer
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
56 publications
2025
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
JAMA
•2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
JAMA network open
•2025
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
JAMA
•2025
Risk prediction for ALS using semi-competing risk models with applications to the ALS Natural History Consortium dataset.
Amyotrophic lateral sclerosis & frontotemporal degeneration
•2025
Time-to-event prediction in ALS using a landmark modeling approach, using the ALS Natural History Consortium dataset.
Amyotrophic lateral sclerosis & frontotemporal degeneration
•